List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9258983/publications.pdf Version: 2024-02-01



DAI-HUL PENC

#	Article	IF	CITATIONS
1	Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. Journal of Affective Disorders, 2022, 296, 258-264.	4.1	3
2	Impaired robust interhemispheric function integration of depressive brain from RESTâ€metaâ€MDD database in China. Bipolar Disorders, 2022, 24, 400-411.	1.9	8
3	Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. Journal of Affective Disorders, 2022, 297, 68-75.	4.1	1
4	A Preliminary Study of Different Treatment Strategies for Anxious Depression. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 11-18.	2.2	0
5	Bilateral Habenula deep brain stimulation for treatment-resistant depression: clinical findings and electrophysiological features. Translational Psychiatry, 2022, 12, 52.	4.8	21
6	Probing the clinical and brain structural boundaries of bipolar and major depressive disorder. Translational Psychiatry, 2021, 11, 48.	4.8	9
7	Disturbances of affective cognition in mood disorders. Science China Life Sciences, 2021, 64, 938-941.	4.9	3
8	Disrupted hemispheric connectivity specialization in patients with major depressive disorder: Evidence from the REST-meta-MDD Project. Journal of Affective Disorders, 2021, 284, 217-228.	4.1	23
9	Gastrointestinal Symptoms During Depressive Episodes in 3256 Patients with Major Depressive Disorders: Findings from the NSSD. Journal of Affective Disorders, 2021, 286, 27-32.	4.1	15
10	Clinical features of the patients with major depressive disorder co-occurring insomnia and hypersomnia symptoms: a report of NSSD study. Sleep Medicine, 2021, 81, 375-381.	1.6	13
11	Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. Journal of Psychiatric Research, 2021, 138, 96-102.	3.1	5
12	Reduced NLRP3 inflammasome expression in the brain is associated with stress resilience. Psychoneuroendocrinology, 2021, 128, 105211.	2.7	9
13	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2441-2449.	2.2	0
14	Disrupted intrinsic functional brain topology in patients with major depressive disorder. Molecular Psychiatry, 2021, 26, 7363-7371.	7.9	82
15	Reward mechanism of depressive episodes in bipolar disorder: Enhanced theta power in feedback-related negativity. Journal of Affective Disorders, 2021, 292, 217-222.	4.1	2
16	Neural biomarker of functional disability in major depressive disorder: A structural neuroimaging study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110337.	4.8	2
17	Brain structural alterations in MDD patients with gastrointestinal symptoms: Evidence from the REST-meta-MDD project. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110386.	4.8	18
18	Signatures of 4 autophagy-related genes as diagnostic markers of MDD and their correlation with immune infiltration. Journal of Affective Disorders, 2021, 295, 11-20.	4.1	20

#	Article	IF	CITATIONS
19	Symptomatology differences of major depression in psychiatric versus general hospitals: A machine learning approach. Journal of Affective Disorders, 2020, 260, 349-360.	4.1	7
20	Causes of drug discontinuation in patients with major depressive disorder in China. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109755.	4.8	23
21	Altered resting-state dynamic functional brain networks in major depressive disorder: Findings from the REST-meta-MDD consortium. Neurolmage: Clinical, 2020, 26, 102163.	2.7	76
22	Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns. NeuroImage: Clinical, 2020, 28, 102514.	2.7	51
23	Altered resting-state fMRI signals and network topological properties of bipolar depression patients with anxiety symptoms. Journal of Affective Disorders, 2020, 277, 358-367.	4.1	12
24	Challenges and opportunities in mental health services during the COVID-19 pandemic. Annals of General Psychiatry, 2020, 33, e100275.	3.1	19
25	<the and="" biomarkers="" characteristics-based<br="" clinical="" developmental="" on="" study="" translational="">Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2343-2351.</the>	2.2	1
26	<p>Individual Perceived Stress Mediates Psychological Distress in Medical Workers During COVID-19 Epidemic Outbreak in Wuhan</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2529-2537.	2.2	18
27	The concurrent disturbance of dynamic functional and structural brain connectome in major depressive disorder: the prefronto-insular pathway. Journal of Affective Disorders, 2020, 274, 1084-1090.	4.1	10
28	The Insular Subregions Topological Characteristics of Patients With Bipolar Depressive Disorder. Frontiers in Psychiatry, 2020, 11, 253.	2.6	7
29	Cortical thickness and subcortical volumes alterations in euthymic bipolar I patients treated with different mood stabilizers. Brain Imaging and Behavior, 2019, 13, 1255-1264.	2.1	8
30	Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China. CNS Neuroscience and Therapeutics, 2019, 25, 215-222.	3.9	8
31	Disagreement and factors between symptom on self-report and clinician rating of major depressive disorder: A report of a national survey in China. Journal of Affective Disorders, 2019, 253, 141-146.	4.1	10
32	Intrinsic gray-matter connectivity of the brain in major depressive disorder. Journal of Affective Disorders, 2019, 251, 78-85.	4.1	17
33	Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9078-9083.	7.1	441
34	Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population. Journal of Affective Disorders, 2019, 249, 82-89.	4.1	12
35	HMGB1 involved in stress-induced depression and its neuroinflammatory priming role: a systematic review. Annals of General Psychiatry, 2019, 32, e100084.	3.1	46
36	The association between somatic symptoms and suicidal ideation in Chinese first-episode major depressive disorder. Journal of Affective Disorders, 2019, 245, 17-21.	4.1	30

#	Article	IF	CITATIONS
37	Neuroimaging Advance in Depressive Disorder. Advances in Experimental Medicine and Biology, 2019, 1180, 59-83.	1.6	4
38	Neuroimaging genomic studies in major depressive disorder: A systematic review. CNS Neuroscience and Therapeutics, 2018, 24, 1020-1036.	3.9	13
39	Prevalence, risk factors and clinical characteristics of suicidal ideation in Chinese patients with depression. Journal of Affective Disorders, 2018, 235, 135-141.	4.1	40
40	The Metabolic Factor Kynurenic Acid of Kynurenine Pathway Predicts Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 552.	2.6	62
41	Effects of tumor necrosis factor-α polymorphism on the brain structural changes of the patients with major depressive disorder. Translational Psychiatry, 2018, 8, 217.	4.8	25
42	Somatic symptoms vary in major depressive disorder in China. Comprehensive Psychiatry, 2018, 87, 32-37.	3.1	37
43	The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. Psychiatry Research, 2018, 269, 251-257.	3.3	18
44	Aberrant Neural Activity in Patients With Bipolar Depressive Disorder Distinguishing to the Unipolar Depressive Disorder: A Resting-State Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry, 2018, 9, 238.	2.6	28
45	Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression. Journal of Affective Disorders, 2018, 237, 65-72.	4.1	47
46	Abnormal white matter integrity in Chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2017-2026.	2.2	13
47	Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: Result from a prospective longitudinal study. Psychoneuroendocrinology, 2017, 81, 113-121.	2.7	21
48	Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC–MS/MS and bioinformatics analysis. Psychoneuroendocrinology, 2017, 86, 17-24.	2.7	51
49	Ratio of mBDNF to proBDNF for Differential Diagnosis of Major Depressive Disorder and Bipolar Depression. Molecular Neurobiology, 2017, 54, 5573-5582.	4.0	62
50	Complement factor H and susceptibility to major depressive disorder in Han Chinese. British Journal of Psychiatry, 2016, 208, 446-452.	2.8	21
51	Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. Journal of Psychiatric Research, 2016, 78, 65-71.	3.1	74
52	Evaluating the association between the SHANK3 gene and bipolar disorder. Psychiatry Research, 2016, 244, 284-288.	3.3	10
53	ZNF804A Genetic Variation Confers Risk to Bipolar Disorder. Molecular Neurobiology, 2016, 53, 2936-2943.	4.0	21
54	Atypical Features and Bipolar Disorder. Shanghai Archives of Psychiatry, 2016, 28, 166-168.	0.7	1

#	Article	IF	CITATIONS
55	Increased Cognition Connectivity Network in Major Depression Disorder: A fMRI Study. Psychiatry Investigation, 2015, 12, 227.	1.6	40
56	Atypical features and treatment choices in bipolar disorders: a result of the National Bipolar Mania Pathway Survey in China. Neuroscience Bulletin, 2015, 31, 22-30.	2.9	4
57	Down-regulation of PRKCB1 expression in Han Chinese patients with subsyndromal symptomatic depression. Journal of Psychiatric Research, 2015, 69, 1-6.	3.1	6
58	Guidelines concordance of maintenance treatment in euthymic patients with bipolar disorder: Data from the national bipolar mania pathway survey (BIPAS) in mainland China. Journal of Affective Disorders, 2015, 182, 101-105.	4.1	6
59	Dissociated large-scale functional connectivity networks of the precuneus in medication-naÃ ⁻ ve first-episode depression. Psychiatry Research - Neuroimaging, 2015, 232, 250-256.	1.8	65
60	Comorbid bipolar disorder and obsessive-compulsive disorder. Shanghai Archives of Psychiatry, 2015, 27, 246-8.	0.7	4
61	Surface Vulnerability of Cerebral Cortex to Major Depressive Disorder. PLoS ONE, 2015, 10, e0120704.	2.5	62
62	Nerve growth factor variations in patients with mood disorders: no changes in eight weeks of clinical treatment. Neuropsychiatric Disease and Treatment, 2014, 10, 835.	2.2	11
63	Alterations in effective connectivity anchored on the insula in major depressive disorder. European Neuropsychopharmacology, 2014, 24, 1784-1792.	0.7	58
64	Altered brain network modules induce helplessness in major depressive disorder. Journal of Affective Disorders, 2014, 168, 21-29.	4.1	57
65	Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neuroscience Letters, 2014, 579, 168-172.	2.1	39
66	Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. Journal of Affective Disorders, 2014, 155, 288-294.	4.1	27
67	Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Research, 2014, 218, 54-60.	3.3	58
68	Guidelines Disconcordance in Acute Bipolar Depression: Data from the National Bipolar Mania Pathway Survey (BIPAS) in Mainland China. PLoS ONE, 2014, 9, e96096.	2.5	11
69	Evaluation of antidepressant polypharmacy and other interventions for treatment-resistant depression. Shanghai Archives of Psychiatry, 2014, 26, 365-7.	0.7	Ο
70	Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: A report of OPERATION study. Journal of Affective Disorders, 2013, 150, 834-839.	4.1	58
71	The extracellular signal-regulated kinase pathway may play an important role in mediating antidepressant-stimulated hippocampus neurogenesis in depression. Medical Hypotheses, 2012, 79, 87-91.	1.5	15
72	Symptom severity is more closely associated with social functioning status in inpatients with schizophrenia than cognitive deficits. Shanghai Archives of Psychiatry, 2012, 24, 83-90.	0.7	0

#	Article	IF	CITATIONS
73	Abnormal functional connectivity with mood regulating circuit in unmedicated individual with major depression: a resting-state functional magnetic resonance study. Chinese Medical Journal, 2012, 125, 3701-6.	2.3	18
74	Decreased regional homogeneity in major depression as revealed by resting-state functional magnetic resonance imaging. Chinese Medical Journal, 2011, 124, 369-73.	2.3	45